PCM
XERS icon

Penserra Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Penserra Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,510
Closed -$6K – 1527
2021
Q2 		$6K Buy
1,510
+155
+11% +$592 ﹤0.01% 1311
2021
Q1 		$6K Buy
1,355
+200
+17% +$1.08K ﹤0.01% 1081
2020
Q4 		$5K Buy
1,155
+761
+193% +$3.81K ﹤0.01% 988
2020
Q3 		$2K Buy
+394
New +$1.57K ﹤0.01% 911

Other funds holding XERS

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Penserra Capital Management's XERS Position: Q3 2021 in Review

Penserra Capital Management sold out of Xeris Biopharma Holdings (XERS) in Q3 2021, closing a stake of 1,510 shares — an estimated $6K sold.

Penserra Capital Management first reported a position in XERS in Q3 2020 and held it in 4 quarters. The position peaked at $6K in Q2 2021. 70 funds tracked by Wall St. Rank hold XERS as of Q3 2021.

  • Penserra Capital Management reported no remaining Xeris Biopharma Holdings position as of Q3 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,510 Xeris Biopharma Holdings shares in Q3 2021, an estimated $6K.
  • Penserra Capital Management first reported a position in Xeris Biopharma Holdings in Q3 2020 and held it in 4 quarters.
  • Penserra Capital Management's Xeris Biopharma Holdings position peaked at $6K in Q2 2021.
  • 70 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2021.

Based on Penserra Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.